Clinical trial · Interventional
The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients
The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients: A Randomized, Double Blind, Controlled, Multi-Center Clinical Trial.
NCT00292279CI-TRIAL-00001456completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate clinical safety and effect of Omega-3 fat oil emulsion on outcome in post-operative cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma Surgery | — | UNRESOLVED | — |
| Parenteral Nutrition | — | UNRESOLVED | — |
| Post-Operative Hospital Stay | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| long-chain triglyceride | Drug | — | UNRESOLVED |
| Omega-3 fish oil emulsion (Omegaven ) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: Omega-3 fish oil emulsion (Omegaven )
- type
- ACTIVE_COMPARATOR
- label
- B
- interventionNames
- Drug: long-chain triglyceride
Primary outcomes (2)
- measure
- Infectious complication
- timeFrame
- POD+1 to POD+14
- measure
- Systemic inflammatory response syndrome (SIRS)
- timeFrame
- POD+1 to POD +8
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Post-operative male and female cancer patients * Require post operative parenteral nutrition support at least 7 days based on nutritional risk screening(BMI 20-25) * Sign an informed consent Exclusion Criteria: * Diabetes Mellitus * Abnormal fatty metabolism (TG\>200mg/dl or cholesterol\>240mg/dl ) * Renal dysfunction (Cr\>1.6mg/dl or BUN\>30mg/dl) * Liver dysfunction (ALT\>60U/L or TBIL\>1.2mg/dl) * Lienectomy * Temperature\>37.5°C * Undergoing hormone therapy * Pregnancy
References
Publications (2)
- RESULT(Abstract) ZM Jiang, XR Wang, JM Wei, Y. Wang, Y. Li, S Wang, DW Wilmore. The impact of i.v. fish oil emulsion on clinical outcome & immune functions of post-operative cancer patients: a randomized, double blind, controlled, multi-center clinical trial for 203 cases Clinical Nutrition(Abstract for ESPEN 2005)(Absract No. 181)
- DERIVEDJiang ZM, Wilmore DW, Wang XR, Wei JM, Zhang ZT, Gu ZY, Wang S, Han SM, Jiang H, Yu K. Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br J Surg. 2010 Jun;97(6):804-9. doi: 10.1002/bjs.6999. PMID 20473991